Non-stimulant treatments of ADHD, atomoxetine and guanfacine, also act to increase monoaminergic neurotransmitter availability; atomoxetine does this by inhibiting the noradrenaline and 5-HT transporters, guanfacine via agonism of the alpha-2 adrenergic receptor [26, 27, 70] and 5-HT receptors [71]. The gene discussed is SLC6A4; the disease is attention deficit-hyperactivity disorder.